MK-1966
Biological
Merck Sharp & Dohme Corporation
Total Payments
$342,244
Transactions
88
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $5,761 | 3 | 0 |
| 2018 | $136,388 | 23 | 0 |
| 2017 | $200,095 | 62 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $342,244 | 88 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1,1b Trial of MK-1966 in Combination with SD-101 in Subjects with Advanced Malignancies | Merck Sharp & Dohme Corporation | $342,244 | 0 |
Top Doctors Receiving Payments for MK-1966
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $342,244 | 88 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $342,244
Product Information
- Type Biological
- Total Payments $342,244
- Total Doctors 0
- Transactions 88
About MK-1966
MK-1966 is a biological associated with $342,244 in payments to 0 healthcare providers, recorded across 88 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $5,761 was paid across 3 transactions to 0 doctors.
The most common payment nature for MK-1966 is "Unspecified" ($342,244, 100.0% of total).
MK-1966 is associated with 1 research study, including "A Phase 1,1b Trial of MK-1966 in Combination with SD-101 in Subjects with Advanced Malignancies" ($342,244).